Immatics N.V.
- IMTX
- NASDAQ
- Biotechnology
- TCR Immunotherapies
- Cancer Immunotherapy
$6.73
Today −5.74%Quote Oct 16, 2026, 08:00 PM UTC
−23.70%over the last month
Max drawdown −24.1%From 1-month high −24.1%3 months −27.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$902.3M
Quote Oct 16
Next earnings
Nov 17
Expected, not confirmed
Analyst target
$16.00
+137.7% from here
Floor
$6.60
1.9% below price
Where the price sits
8 analysts
Analyst range, low to high
$15.00$17.00
- Price $6.73
- Resistance $7.02
- Consensus $16.00
The price is just above its floor. Analysts' average target sits about 138% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about IMTXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
704